GAITHERSBURG, Md., Aug. 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has granted expanded conditional marketing authorization (CMA) for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.
"As we start to prepare for a potential fall surge, we are pleased to offer the first protein-based COVID-19 vaccine to adolescents aged 12 through 17 in the U.K.," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We believe that our vaccine, developed using an innovative approach to traditional technology, may help increase adolescent vaccination rates."
The expanded CMA was based on data from the ongoing pediatric expansionof the Phase 3 PREVENT-19 trial of 2,247 adolescents aged 12 through 17 years across 73 sites in the U.S., to evaluate the safety, effectiveness (immunogenicity), and efficacy of Nuvaxovid. In the pediatric expansion, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.
Preliminary safety data from the pediatric expansion showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, and not considered related to the vaccine. Local and systemic reactogenicity was generally lower than or similar to adults, after the first and second dose. The most common adverse reactions observed were injection site tenderness/pain, headache, myalgia, fatigue, and malaise. There was no increase in reactogenicity in younger (12 to <15 years old) adolescents compared to older (15 to <18 years old) adolescents. No new safety signal was observed through the placebo-controlled portion of the pediatric expansion.
The next step for the vaccine is a policy recommendation for use from the UK Joint Committee on Vaccination and Immunisation (JCVI). Doses of Nuvaxovid will be made available for use in adolescents based on the JCVI's recommendation.
In the 12 through 17 year-old population, the Novavax COVID-19 vaccine has been granted authorization in the U.S., India, the European Union, Australia, Japan, Thailand, and New Zealand, and is actively under review in other markets.
The MHRA previously granted CMA for Nuvaxovid in adults aged 18 and older in February 2022. The vaccine is given as a primary vaccination in two doses administered 21 days apart. Novavax filed for expanded CMA for use as a booster in adults aged 18 and over in June 2022.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you are concerned about an adverse event, it should be reported on a Yellow Card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/or search for MHRA Yellow Card in the Google Play or Apple App Store. When reporting please include the vaccine brand and batch/Lot number if available.
Trade Name in the U.S.The trade name Nuvaxovid has not yet been approved by the U.S. Food and Drug Administration.
Important Safety Information: UK
For more information on Nuvaxovid, including the Summary of Product Characteristics with Package Leaflet, adverse event reporting instructions, or to request additional information, please visit the following websites:
About Nuvaxovid (NVX-CoV2373)Nuvaxovid (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Nuvaxovid contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Nuvaxovid is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2- 8 Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.
Novavax has established partnerships for the manufacture, commercialization, and distribution of Nuvaxovid worldwide. Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India, the world's largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax' global supply chain.
About the Novavax COVID-19 vaccine (NVX-CoV2373) Phase 3 TrialsThe Novavax COVID-19 vaccine (NVX-CoV2373) continues being evaluated in two pivotal Phase 3 trials.
PREVENT-19 (thePRE-fusion protein subunitVaccineEfficacyNovavaxTrial | COVID-19) is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the efficacy, safety and immunogenicity of the Novavax COVID-19 vaccine with Matrix-M adjuvant in 29,960 participants 18 years of age and over in 119 locations inthe U.S.andMexico. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. In the trial, the Novavax COVID-19 vaccine achieved 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in theNew England Journal of Medicine(NEJM).
The pediatric expansion of PREVENT-19 is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the safety, effectiveness, and efficacy of the Novavax COVID-19 vaccine with Matrix-M adjuvant in 2,247 adolescent participants 12 to 17 years of age in 73 locations in the United States, compared with placebo. In the pediatric trial, the vaccine achieved its primary effectiveness endpoint (non-inferiority of the neutralizing antibody response compared to young adult participants 18 through 25 years of age from PREVENT-19) and demonstrated 80% efficacy overall at a time when the Delta variant of concern was the predominant circulating strain in the U.S.Additionally, immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied.
Additionally, a trial conducted in the U.K. with 14,039 participants aged 18 years and over was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published inNEJM.
About Matrix-M AdjuvantNovavax' patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
About NovavaxNovavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine, has received authorization from multiple regulatory authorities globally, including the U.S., EC and the WHO. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine candidate in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate, and is also evaluating an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visitwww.novavax.comand connect with us on LinkedIn.
*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.
Forward-Looking StatementsStatements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the potential for subsequent orders from the U.S. government for additional doses of NVX-CoV2373 and other potential formulations, the timing of clinical trial results, the ongoing development of NVX-CoV2373, including an Omicron strain based vaccine and bivalent Omicron-based / original strain based vaccine, a COVID-seasonal influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax' plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax' global supply chain, additional worldwide authorizations of NVX-CoV2373 for use in adults and adolescents, and as a booster, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, the efficacy, safety and intended utilization of NVX-CoV2373, and the expected administration of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; unanticipated challenges or delays in conducting clinical trials; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at http://www.sec.gov and http://www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
InvestorsErika Schultz | 240-268-2022[emailprotected]
MediaAli Chartan or Giovanna Chandler | 202-709-5563[emailprotected]
SOURCE Novavax, Inc.
View original post here:
Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through...
- Genetic Engineering (excerpt) - Video [Last Updated On: January 9th, 2012] [Originally Added On: January 9th, 2012]
- Promising early results with therapeutic cancer vaccines [Last Updated On: February 16th, 2012] [Originally Added On: February 16th, 2012]
- Genetic Risk and Stressful Early Infancy Join to Increase Risk for Schizophrenia [Last Updated On: March 27th, 2012] [Originally Added On: March 27th, 2012]
- Innovative cell printing technologies hold promise for tissue engineering R&D [Last Updated On: March 28th, 2012] [Originally Added On: March 28th, 2012]
- SAGE® Labs Creates The First Tissue-Specific Gene Deletion In Rats [Last Updated On: April 21st, 2012] [Originally Added On: April 21st, 2012]
- Devangshu Datta: Towards an HIV cure [Last Updated On: May 5th, 2012] [Originally Added On: May 5th, 2012]
- Now *This* Is a Cell Phone: Using Radio Waves to Control Specific Genes in Mice | 80beats [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- Genetic packing: Successful stem cell differentiation requires DNA compaction, study finds [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- Premier issue of BioResearch Open Access launched by Mary Ann Liebert Inc. publishers [Last Updated On: May 17th, 2012] [Originally Added On: May 17th, 2012]
- GEN reports on growth of tissue engineering revenues [Last Updated On: July 11th, 2012] [Originally Added On: July 11th, 2012]
- New therapeutic target for prostate cancer identified [Last Updated On: July 18th, 2012] [Originally Added On: July 18th, 2012]
- Novel pig model may be useful for human cancer studies [Last Updated On: July 24th, 2012] [Originally Added On: July 24th, 2012]
- New gene therapy strategy boosts levels of deficient protein in Friedreich's ataxia [Last Updated On: July 25th, 2012] [Originally Added On: July 25th, 2012]
- Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma? [Last Updated On: July 26th, 2012] [Originally Added On: July 26th, 2012]
- New marker for identifying precursors to insulin-producing cells in pancreas [Last Updated On: August 22nd, 2012] [Originally Added On: August 22nd, 2012]
- 3D Biomatrix’s Perfecta3D® Hanging Drop Plates Featured in Prominent Life Science Journals [Last Updated On: October 1st, 2012] [Originally Added On: October 1st, 2012]
- Progress in Cell-SELEX compound screening technology reviewed in BioResearch Open Access [Last Updated On: October 18th, 2012] [Originally Added On: October 18th, 2012]
- Can the addition of radiolabeled treatments improve outcomes in advanced metastatic disease? [Last Updated On: November 14th, 2012] [Originally Added On: November 14th, 2012]
- Is the detection of early markers of Epstein Barr virus of diagnostic value? [Last Updated On: November 18th, 2012] [Originally Added On: November 18th, 2012]
- Genetic Engineering Of Mesenchymal Stem Cells - Video [Last Updated On: November 18th, 2012] [Originally Added On: November 18th, 2012]
- Ramble: Simelweis Taboo - Video [Last Updated On: December 12th, 2012] [Originally Added On: December 12th, 2012]
- The Super Protein That Can Cut DNA and Revolutionize Genetic Engineering [Last Updated On: March 22nd, 2013] [Originally Added On: March 22nd, 2013]
- Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents [Last Updated On: June 5th, 2013] [Originally Added On: June 5th, 2013]
- World Stem Cell Summit to be presented by Genetics Policy Institute, Mary Ann Liebert, Inc., and Genetic Engineering ... [Last Updated On: June 11th, 2013] [Originally Added On: June 11th, 2013]
- Genetic engineering - Wikipedia, the free encyclopedia [Last Updated On: November 1st, 2013] [Originally Added On: November 1st, 2013]
- Genetic Engineering: What is Genetic Engineering? [Last Updated On: November 1st, 2013] [Originally Added On: November 1st, 2013]
- Critical factor (BRG1) identified for maintaining stem cell pluripotency [Last Updated On: February 7th, 2014] [Originally Added On: February 7th, 2014]
- Genome Surgery [Last Updated On: February 11th, 2014] [Originally Added On: February 11th, 2014]
- Engineering The Human Genome One Letter At A Time [Last Updated On: February 11th, 2014] [Originally Added On: February 11th, 2014]
- CRISPR is the technology that could allow researchers to perform microsurgery on genes [Last Updated On: February 15th, 2014] [Originally Added On: February 15th, 2014]
- Joseph Glorioso, Ph.D., receives Pioneer Award [Last Updated On: February 19th, 2014] [Originally Added On: February 19th, 2014]
- Commentary: field of tissue engineering is progressing at remarkable pace [Last Updated On: March 5th, 2014] [Originally Added On: March 5th, 2014]
- Pioneer Award recipients Marina Cavazzana and Adrian Thrasher recognized for advancing gene therapy to the clinic for ... [Last Updated On: March 24th, 2014] [Originally Added On: March 24th, 2014]
- New method yields potent, renewable human stem cells with promising therapeutic properties [Last Updated On: March 25th, 2014] [Originally Added On: March 25th, 2014]
- First evidence that very small embryonic-like stem cells [Last Updated On: April 2nd, 2014] [Originally Added On: April 2nd, 2014]
- Scarless wound healing -- applying lessons learned from fetal stem cells [Last Updated On: April 11th, 2014] [Originally Added On: April 11th, 2014]
- Novel marker discovered for stem cells derived from human umbilical cord blood [Last Updated On: April 18th, 2014] [Originally Added On: April 18th, 2014]
- GENs Top 10 Session Picks for the 2014 BIO International Convention [Last Updated On: May 2nd, 2014] [Originally Added On: May 2nd, 2014]
- A Vaccine for Heart Disease Could Mean No Pills, Lettuce or a Gym [Last Updated On: June 14th, 2014] [Originally Added On: June 14th, 2014]
- Gene editing tool can write HIV out of the picture [Last Updated On: June 22nd, 2014] [Originally Added On: June 22nd, 2014]
- Inner ear stem cells hold promise for restoring hearing [Last Updated On: June 24th, 2014] [Originally Added On: June 24th, 2014]
- New method to grow zebrafish embryonic stem cells can regenerate whole fish [Last Updated On: June 30th, 2014] [Originally Added On: June 30th, 2014]
- Novel methods may help stem cells survive transplantation into damaged tissues [Last Updated On: July 22nd, 2014] [Originally Added On: July 22nd, 2014]
- New method for reducing tumorigenicity in induced pluripotent stem-cell based therapies [Last Updated On: July 24th, 2014] [Originally Added On: July 24th, 2014]
- Malcolm K. Brenner receives Pioneer Award for advances in gene-modified T cells targeting cancer [Last Updated On: July 26th, 2014] [Originally Added On: July 26th, 2014]
- Conclusive evidence on role of circulating mesenchymal stem cells in organ injury [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- New genomic editing methods produce better disease models from patient-derived iPSCs [Last Updated On: September 8th, 2014] [Originally Added On: September 8th, 2014]
- Tory Williams combats controversy surrounding stem cell therapy with new book [Last Updated On: September 11th, 2014] [Originally Added On: September 11th, 2014]
- NYIT Expert Predicts Growth in Demand for 3D Kidneys, Livers and Hearts [Last Updated On: December 9th, 2014] [Originally Added On: December 9th, 2014]
- The 'Berlin patient,' first and only person cured of HIV, speaks out [Last Updated On: January 6th, 2015] [Originally Added On: January 6th, 2015]
- Integrins are essential in stem cell binding to defective cartilage for joint regeneration [Last Updated On: January 27th, 2015] [Originally Added On: January 27th, 2015]
- Scientists urge caution in using new CRISPR technology to treat human genetic disease [Last Updated On: March 20th, 2015] [Originally Added On: March 20th, 2015]
- Scientists call for caution in using DNA-editing technology [Last Updated On: March 23rd, 2015] [Originally Added On: March 23rd, 2015]
- 'Ban DNA Editing Of Sperm And Eggs' [Last Updated On: March 23rd, 2015] [Originally Added On: March 23rd, 2015]
- Mount Sinai Researchers Discover Genetic Origins of Myelodysplastic Syndrome Using Stem Cells [Last Updated On: March 26th, 2015] [Originally Added On: March 26th, 2015]
- Researchers discover genetic origins of myelodysplastic syndrome using stem cells [Last Updated On: March 26th, 2015] [Originally Added On: March 26th, 2015]
- Pulling the strings of our genetic puppetmasters [Last Updated On: April 6th, 2015] [Originally Added On: April 6th, 2015]
- Going deep on life extension investments and human genetic engineering (Morning Read) [Last Updated On: April 6th, 2015] [Originally Added On: April 6th, 2015]
- Genetic engineering: a guide for kids by Tiki the Penguin [Last Updated On: July 8th, 2015] [Originally Added On: July 8th, 2015]
- genetic engineering | Britannica.com [Last Updated On: July 20th, 2015] [Originally Added On: July 20th, 2015]
- Interactives . DNA . Genetic Engineering [Last Updated On: August 3rd, 2015] [Originally Added On: August 3rd, 2015]
- Genetic engineering - Memory Alpha, the Star Trek Wiki [Last Updated On: September 10th, 2015] [Originally Added On: September 10th, 2015]
- Genetic Engineering Careers in India : How to become a ... [Last Updated On: September 10th, 2015] [Originally Added On: September 10th, 2015]
- Genetic Engineering (song) - Wikipedia, the free encyclopedia [Last Updated On: August 8th, 2016] [Originally Added On: August 8th, 2016]
- Genetic Engineering - BiologyMad [Last Updated On: September 28th, 2016] [Originally Added On: September 28th, 2016]
- UNL's AgBiosafety for Educators [Last Updated On: September 28th, 2016] [Originally Added On: September 28th, 2016]
- Recent Articles | Genetic Engineering | The Scientist ... [Last Updated On: October 20th, 2016] [Originally Added On: October 20th, 2016]
- Human Genetic Engineering - Popular Issues [Last Updated On: October 29th, 2016] [Originally Added On: October 29th, 2016]
- Explore More: Genetic Engineering - iptv.org [Last Updated On: October 29th, 2016] [Originally Added On: October 29th, 2016]
- Genetic Engineering and GM Crops - Pocket K | ISAAA.org [Last Updated On: November 10th, 2016] [Originally Added On: November 10th, 2016]
- Pros and Cons of Genetic Engineering | HRFnd [Last Updated On: November 10th, 2016] [Originally Added On: November 10th, 2016]
- Genetic Engineering - The New York Times [Last Updated On: November 10th, 2016] [Originally Added On: November 10th, 2016]
- Genetic Engineering | MSPCA-Angell [Last Updated On: November 10th, 2016] [Originally Added On: November 10th, 2016]
- What is genetic engineering? - Definition from WhatIs.com [Last Updated On: November 10th, 2016] [Originally Added On: November 10th, 2016]
- Genetic Engineering in Agriculture | Union of Concerned ... [Last Updated On: November 16th, 2016] [Originally Added On: November 16th, 2016]
- Free genetic engineering Essays and Papers - 123helpme [Last Updated On: November 20th, 2016] [Originally Added On: November 20th, 2016]
- Gene therapy - Wikipedia [Last Updated On: November 20th, 2016] [Originally Added On: November 20th, 2016]
- Writing the human genome - The Biological SCENE [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]
- America's First Free-Roaming Genetically Engineered Insects Are ... - Gizmodo [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]
- Stanford's Final Exams Pose Question About the Ethics of Genetic Engineering - Futurism [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]